Ceftobiprole medocaril

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Ceftobiprole medocaril
Accession Number
DB14733
Type
Small Molecule
Groups
Experimental, Investigational
Description

Ceftobiprole medocaril is a ceftobiprole prodrug.

Structure
Thumb
Synonyms
  • Ceftobiprole medocaril
  • Ceftobiprole medocaril free acid
Product Ingredients
IngredientUNIICASInChI Key
Ceftobiprole medocaril sodiumN99027V28J252188-71-9MFAWUGGPPMTWPU-LCJFHXTKSA-M
Categories
UNII
YXV28V1B07
CAS number
376653-43-9
Weight
Average: 690.66
Monoisotopic: 690.116246037
Chemical Formula
C26H26N8O11S2
InChI Key
HFTSMHTWUFCYMJ-YIOMYIDASA-N
InChI
InChI=1S/C26H26N8O11S2/c1-10-14(45-26(41)44-10)8-43-25(40)32-4-3-13(7-32)33-5-2-11(20(33)36)6-12-9-46-22-16(21(37)34(22)17(12)23(38)39)28-19(35)15(30-42)18-29-24(27)47-31-18/h6,13,16,22,42H,2-5,7-9H2,1H3,(H,28,35)(H,38,39)(H2,27,29,31)/b11-6+,30-15-/t13-,16-,22-/m1/s1
IUPAC Name
SMILES
[H][C@@]1(NC(=O)C(=N/O)\C2=NSC(N)=N2)C(=O)N2C(C(O)=O)=C(CS[C@]12[H])\C=C1/CCN(C1=O)[C@]1([H])CCN(C1)C(=O)OCC1=C(C)OC(=O)O1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe risk or severity of bleeding can be increased when Ceftobiprole medocaril is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of bleeding can be increased when Ceftobiprole medocaril is combined with (S)-Warfarin.
4-hydroxycoumarinThe risk or severity of bleeding can be increased when Ceftobiprole medocaril is combined with 4-hydroxycoumarin.
AcenocoumarolThe risk or severity of bleeding can be increased when Ceftobiprole medocaril is combined with Acenocoumarol.
Adenovirus type 7 vaccine liveThe therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Ceftobiprole medocaril.
Anthrax immune globulin humanThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Ceftobiprole medocaril.
Anthrax vaccineThe therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Ceftobiprole medocaril.
Bacillus calmette-guerin substrain connaught live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Ceftobiprole medocaril.
Bacillus calmette-guerin substrain danish 1331 live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Ceftobiprole medocaril.
Bacillus calmette-guerin substrain tice live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Ceftobiprole medocaril.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
28475342
ChEBI
135968
Wikipedia
Ceftobiprole
ATC Codes
J01DI01 — Ceftobiprole medocaril

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2RecruitingTreatmentInflamed Meninges / Suspected Meningitis / Ventriculitis1
2WithdrawnTreatmentBacteremia1
3CompletedTreatmentPneumonia1
3CompletedTreatmentSkin Diseases, Bacterial / Skin Diseases, Infectious / Staphylococcal Skin Infections2
3RecruitingTreatmentCommunity Acquired Pneumonia (CAP) / Pneumonia, Hospital-Acquired1
3RecruitingTreatmentStaphylococcus Aureus Bacteraemia1
3RecruitingTreatmentAcute acute bacterial skin and skin structure infections1
3TerminatedTreatmentFevers / Infections, Gram-Positive Bacterial / Neutropenias / Pseudomonas Infections1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on January 27, 2019 14:57 / Updated on May 01, 2019 13:35